Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice


Foxo-1, a member of the Foxo forkhead type transcription factors, is markedly upregulated in skeletal muscle in energy-deprived states such as fasting, cancer and severe diabetes. In this study, we target the Foxo-1 mRNA in a mouse skeletal myoblast cell line C2C12 and in vivo models of normal and cancer cachexia mice by a Foxo-1 specific RNA oligonucleotide. Our results demonstrate that the RNA oligonucleotide can reduce the expression of Foxo-1 in cells and in normal and cachectic mice, leading to an increase in skeletal muscle mass of the mice. In search for the possible downstream target genes of Foxo-1, we show that when Foxo-1 expression is blocked both in cells and in mice, the level of MyoD, a myogenic factor, is increased while a muscle negative regulator GDF-8 or myostatin is suppressed. Taken together, these results show that Foxo-1 pays a critical role in development of muscle atrophy, and suggest that Foxo-1 is a potential molecular target for treatment of muscle wasting conditions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others


  1. Lynch GS, Schertzer JD, Ryall JG . Therapeutic approaches for muscle wasting disorders. Pharmacol Ther 2007; 113: 461–872.

    Article  CAS  Google Scholar 

  2. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, Emanuel BS et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230–235.

    Article  CAS  Google Scholar 

  3. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, downregulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 279: 41114–41123.

    Article  CAS  Google Scholar 

  4. Bois PR, Grosveld GC . FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J 2003; 22: 1147–1157.

    Article  CAS  Google Scholar 

  5. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NSB, Lam EWF et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000; 20: 9138–9148.

    Article  CAS  Google Scholar 

  6. Medema RH, Kops GJ, Bos JL, Burgering BMT . AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404: 782–787.

    Article  CAS  Google Scholar 

  7. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999; 96: 857–868.

    Article  CAS  Google Scholar 

  8. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KWA, Coffer PJ et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002; 419: 316–321.

    Article  CAS  Google Scholar 

  9. Grobet L, Pirottin D, Farnir F . Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the GDF-8 gene. Genesis 2003; 35: 227–238.

    Article  CAS  Google Scholar 

  10. Lee SJ, McPherron AC . 2001) Regulation of GDF-8 activity and muscle growth. Proc Natl Acad Sci USA 2001; 98: 9306–9311.

    Article  CAS  Google Scholar 

  11. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of GDF-8. Am J Physiol Endocrinol Metab 2003; 285: E876–E888.

    Article  CAS  Google Scholar 

  12. Wehling M, Cai B, Tidball JG . Modulation of GDF-8 expression during modified muscle use. FASEB J 2000; 14: 103–110.

    Article  CAS  Google Scholar 

  13. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL . Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995; 268: E996–E1006.

    CAS  PubMed  Google Scholar 

  14. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.

    Article  CAS  Google Scholar 

  15. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore L, Ahima RS et al. Functional improvement of dystrophic muscle by GDF-8 blockade. Nature 2002; 28: 418–421.

    Article  Google Scholar 

  16. Joulia D, Bernardi H, Garandel V, Rabenoelina F, Vernus B, Cabello G . Mechanisms involved in the inhibition of myoblast proliferation and differentiation by GDF-8. Exp Cell Res 2003; 286: 263–275.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to P Tien or L-Q Sun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, CM., Yang, Z., Liu, CW. et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 14, 945–952 (2007).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links